Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Effects of Dapagliflozin on Lipoprotein Kinetics in Type 2 Diabetes
NCT03269058Phase 4Completed
- Sponsor
- Centre Hospitalier Universitaire Dijon Bourgogne
- Start
- Dec 2017
- Primary completion
- May 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised trial of dapagliflozin in type 2 diabetes mellitus (T2DM) (2 arms), sponsored by Centre Hospitalier Universitaire Dijon Bourgogne. Primary endpoints: Rate of production of VLDL Apo B at 180 days, Rate of production of IDL Apo B at 180 days and 7 more. Started Dec 2017; status: completed.
02
Drugs
dapagliflozin
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT03269058.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03269058.